PDCD1 and melanoma: In this large, single health care network, retrospective cohort study evaluating the incidence of all-cause AKI, ICI-associated AKI, and CKD in patients with advanced melanoma treated with ICIs, we found that all-cause AKI incidence was substantially higher among patients with stage 4 melanoma compared to those stage 3 melanoma, whereas the risk of ICI-associated AKI was similar between stage 3 and stage 4 patients treated with anti-PD-1 therapy, and only higher among patients with stage 4 melanoma who received anti-CTLA-4/PD-1 combination therapy.